Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis

Arthritis Research and Therapy

Volumn 12, Issue 6, 2010, Pages

  Larsson, Staffan ^a   Englund, Martin ^a,b   Struglics, André ^a   Lohmander, L Stefan ^a  

^a LUND UNIVERSITY   (Sweden)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MENISCECTOMY; SYNOVIAL FLUID; AGED; CHEMISTRY; METABOLISM; MIDDLE AGED; RADIOGRAPHY; WESTERN BLOTTING;

ADULT; AGED; AGGRECANS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHEMILUMINESCENT MEASUREMENTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; SYNOVIAL FLUID;

EID: 78650637016     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3217     Document Type: Article

References (46)

1. Sandy JD. Proteolytic degradation of normal and osteoarthritic cartilage matrix. Osteoarthritis 2003, 82-92. Oxford: Oxford University Press, Brandt KD, Doherty M, Lohmander LS, 2.
2. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996, 98:2292-2299. 10.1172/JCI119040, 507679, 8941646.
3. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001, 60:619-626. 10.1136/ard.60.6.619, 1753666, 11350852.
4. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139. 10.1002/art.11326, 14613275.
5. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648. 10.1038/nature03369, 15800624.
6. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652. 10.1038/nature03417, 15800625.
7. Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 2006, 14:1189-1195. 10.1016/j.joca.2006.04.009, 16753310.
8. Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380. 10.1002/art.24473, 19404937.
9. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009, 17:384-389. 10.1016/j.joca.2008.07.009, 18768336.
10. Larsson S, Lohmander LS, Struglics A. Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther 2009, 11:R92. 10.1186/ar2735, 2714148, 19545413.
11. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733. 10.1002/art.25002, 2832925, 19950295.
12. Struglics A, Larsson S, Hansson M, Lohmander LS. Western blot quantification of aggrecan fragments in human synovial fluid indicates differences in fragment patterns between joint diseases. Osteoarthritis Cartilage 2009, 17:497-506. 10.1016/j.joca.2008.09.017, 19095471.
13. Pratta MA, Yao WQ, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003, 278:45539-45545. 10.1074/jbc.M303737200, 12890681.
14. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegård D, Jordan JM, Kepler TB, Lane NE, Saxne T, Tyree B, Kraus VB. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006, 14:723-727. 10.1016/j.joca.2006.04.001, 16733093.
15. Kraus VB. Biomarkers in osteoarthritis. Curr Opin Rheumatol 2005, 17:641-646. 10.1097/01.bor.0000174195.15421.17, 16093846.
16. Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007, 3:346-356. 10.1038/ncprheum0508, 17538566.
17. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004, 50:2471-2478. 10.1002/art.20332, 15334460.
18. Lohmander LS, Dahlberg L, Ryd L, Heinegård D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 1989, 32:1434-1442. 10.1002/anr.1780321113, 2554931.
19. Dahlberg L, Ryd L, Heinegård D, Lohmander LS. Proteoglycan fragments in joint fluid: influence of arthrosis and inflammation. Acta Orthop Scand 1992, 63:417-423. 10.3109/17453679209154758, 1529693.
20. Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Björnsson S, Lark MW. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993, 20:1362-1368.
21. Saxne T, Glennås A, Kvien TK, Melby K, Heinegård D. Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum 1993, 36:20-25. 10.1002/art.1780360105, 7678742.
22. Englund M, Roos EM, Lohmander LS. Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteen-year followup of meniscectomy with matched controls. Arthritis Rheum 2003, 48:2178-2187. 10.1002/art.11088, 12905471.
23. Englund M, Lohmander LS. Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum 2004, 50:2811-2819. 10.1002/art.20489, 15457449.
24. Englund M, Lohmander LS. Patellofemoral osteoarthritis coexistent with tibiofemoral osteoarthritis in a meniscectomy population. Ann Rheum Dis 2005, 64:1721-1726. 10.1136/ard.2005.035568, 1755313, 15843446.
25. Peterfy C, Li J, Zaim S, Duryea J, Lynch J, Miaux Y, Yu W, Genant HK. Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol 2003, 32:128-132. 10.1007/s00256-002-0603-z, 12605275.
26. Kothari M, Guermazi A, von Ingersleben G, Miaux Y, Sieffert M, Block JE, Stevens R, Peterfy CG. Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol 2004, 14:1568-1573. 10.1007/s00330-004-2312-6, 15150666.
27. Altman RD, Hochberg M, Murphy WA, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage 1995, 3(suppl A):3-70.
28. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:101-113. 10.1016/j.joca.2005.07.018, 16188468.
29. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999, 284:1664-1666. 10.1126/science.284.5420.1664, 10356395.
30. Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:702-713. 10.1016/j.joca.2006.01.012, 16549371.
31. Swearingen CA, Carpenter JW, Siegel R, Brittain IJ, Dotzlaf J, Durham TB, Toth JL, Laska DA, Marimuthu J, Liu C, Brown DP, Carter QL, Wiley MR, Duffin KL, Mitchell PG, Thirunavukkarasu K. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage 2010, 18:1150-1158. 10.1016/j.joca.2010.06.011, 20633682.
32. Deaver DR. A new non-isotopic detection system for immunoassays. Nature 1995, 377:758-760. 10.1038/377758a0, 7477271.
33. Guglielmo-Viret V, Thullier P. Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J Immunol Methods 2007, 328:70-78. 10.1016/j.jim.2007.08.003, 17854822.
34. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009, 340:55-64. 10.1016/j.jim.2008.10.002, 18983846.
35. Chockalingam PS, Sun W, Rivera-Bermudez MA, Zeng W, Dufield DR, Larsson S, Lohmander LS, Flannery CR, Glasson SS, Georgiadis KE, Morris EA. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage
36. Doege KJ, Sasaki M, Kimura T, Yamada Y. Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan: human-specific repeats, and additional alternatively spliced forms. J Biol Chem 1991, 266:894-902.
37. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992, 90:2268-2277. 10.1172/JCI116113, 443378, 1281828.
38. Lohmander LS, Ionescu M, Jugessur H, Poole AR. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999, 42:534-544. 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J, 10088777.
39. Lohmander LS, Poole AR. Defining and validating the clinical role of molecular markers in osteoarthritis. Osteoarthritis 2003, 468-477. Oxford: Oxford University Press, Brandt KD, Doherty M, Lohmander LS, 2.
40. Simkin PA, Bassett JE. Cartilage matrix molecules in serum and synovial fluid. Curr Opin Rheumatol 1995, 7:346-351. 10.1097/00002281-199507000-00014, 7547113.
41. Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage 1998, 6:351-361. 10.1053/joca.1998.0134, 10197170.
42. Saxne T, Heinegård D, Wollheim FA, Pettersson H. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet 1985, 2:127-128. 10.1016/S0140-6736(85)90229-6, 2862321.
43. Saxne T, Heinegård D, Wollheim FA. Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann Rheum Dis 1986, 45:491-497. 10.1136/ard.45.6.491, 1001921, 3729574.
44. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992, 89:1512-1516. 10.1172/JCI115742, 443022, 1569188.
45. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993, 36:1214-1222. 10.1002/art.1780360906, 8216415.
46. Kraus VB, Nevitt M, Sandell LJ. Summary of the OA Biomarkers Workshop 2009 Biochemical Biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage 2010, 18:742-745. 10.1016/j.joca.2010.02.014, 20206708.